Trial · NCT06898515
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515, Not applicable, Recruiting, Reprieve Cardiovascular, Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258). Trials, record NCT06898515. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06898515
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
- NCT number
- NCT06898515
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Reprieve Cardiovascular, Inc
- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Reprieve System, furosemide infusion
- First posted
- 2025-03-27
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hierarchical composite/win-ratio | 1. up to 30 days from randomization, 2. up to 30 days from discharge, 3. up to 72 hours after randomization | 1. Freedom from 30-day CV mortality 2. Freedom from HF Rehospitalization 30 days post-discharge 3. Greater net sodium loss per 24 hours during treatment |
| Primary | Incidence of device/procedure-related adverse events (KDIGO stage 2 or greater AKI, CAUTI) | initiation of randomized therapy through 72 hours following completion of randomized therapy | KDIGO stage 2 or greater AKI: ≥ doubling of serum creatinine or use of renal replacement therapy; CAUTI per CDC definition |
| Secondary | Net sodium loss | per 24 hours at end of randomized therapy | |
| Secondary | Time to discharge readiness | through hospital discharge, an average of 5 days | Time from initiation of randomized therapy to when the participant becomes medically ready for discharge from a decompensated heart failure treatment standpoint |
| Secondary | Time on IV diuretic therapy | randomization through hospital discharge, assessed up to 30 days | |
| Secondary | Net fluid loss | per 24 hours at end of randomized therapy | Fluid input subtracted from total urine output |
| Secondary | Weight loss | per 24 hours at end of randomized therapy | |
| Secondary | CV mortality and cumulative HF rehospitalizations | 90 days after hospital discharge | Both types of events will be combined in a total "event rate" compared between groups |
| Secondary | Length of stay | through hospital discharge, an average of 5 days | Time from initiation of randomized therapy to hospital discharge |
| Secondary | Hypotension defined as systolic blood pressure < 80 mmHg documented with two readings at least 30 minutes apart with symptoms (e.g., chest pain, dizziness) or <80 mmHg requiring an intervention including IV fluids or vasopressors. | initiation of randomized therapy up to 12 hours after stopping randomized therapy |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06898515
GET https://conductscience.org/api/trials/v1/NCT06898515/registered